Education:
Prof. Xichun Hu’s educational background is distinguished and extensive. He completed his Bachelor of Medicine at Suzhou Medical College from September 1983 to July 1988. He pursued further specialization in oncology by obtaining a Master of Oncology from Shanghai Medical University Graduate School between September 1988 and July 1991. Prof. Hu then advanced his expertise with a Doctorate from The University of Hong Kong, where he studied from April 1998 to November 2001. His commitment to continuous learning is evident from his participation in advanced training programs, including the Hospital Management Advanced Training Program for Middle-level Cadres at Cancer Otolaryngology Hospital in 2006, and Clinical Trials in Oncology at Vienna School of Clinical Research, Shanghai in 2006. Additionally, he underwent Clinical Trials Training at Mayo Clinic, USA, in 2007, where he was awarded the ICRE fellow by the National Foundation for Cancer Research, further showcasing his dedication to advancing his knowledge and skills in the field of oncology.
Professional Experience:
Prof. Xichun Hu’s extensive professional career in oncology spans several decades. He began as a Resident Physician at Shanghai Medical University Cancer Hospital from July 1988 to June 1994, where he honed his clinical skills. He was promoted to Attending Physician at the same institution from June 1994 to March 1998. His career progressed as he took on the role of Attending Physician at Fudan University Cancer Hospital from December 2001 to November 2002. Prof. Hu was subsequently appointed Associate Chief Physician at Fudan University Cancer Hospital, serving from November 2002 to April 2008. He also held the position of Executive Vice President at the hospital’s Minhang Branch from December 2006 to March 2008. Since April 2008, Prof. Hu has been a Chief Physician and Professor at Fudan University Cancer Hospital, where he continues to lead and innovate in oncology treatment. His roles have included Doctoral Supervisor (2012–present), Deputy Director of the Chemotherapy Department (February 2006 – December 2014), Acting Deputy Director of the Oncology Department (December 2014 – March 2016), and Executive Deputy Director of the Clinical Trial Institution (March 2016 – present). He has been the Director of the Oncology Department since June 2016, shaping the future of cancer care through his leadership and expertise.
Research Interests:
Prof. Xichun Hu’s research interests are deeply rooted in oncology, with a focus on advancing the treatment and understanding of breast cancer. His work explores various dimensions of cancer biology and therapy, including hormone receptor-positive and HER2-negative advanced breast cancer, and the heterogeneity between primary and metastatic cancer. Prof. Hu investigates the efficacy of novel treatments such as Pyrotinib plus capecitabine for trastuzumab-resistant HER2-positive breast cancer. His research also delves into immune resistance mechanisms, particularly in triple-negative breast cancer, and the role of chromatin remodeling molecules like ARID1A in metastatic heterogeneity. Additionally, he is engaged in clinical and preclinical studies of new therapies, such as the highly selective HER2 inhibitor DZD1516, and the novel anti-PD-L1 monoclonal antibody MSB2311. Prof. Hu’s research aims to improve early diagnosis, treatment strategies, and survival outcomes for breast cancer patients, particularly those with recurrent and metastatic forms of the disease.
Publications:
Prof. Hu has authored 305 papers, including key publications in top-tier SCI journals. His research covers critical areas such as hormone receptor-positive breast cancer, HER2-low breast cancer heterogeneity, and novel cancer therapies. His work, including recent publications in prestigious journals like Cancer Med and BMC Med, highlights his ongoing contributions to advancing oncology.
Conclusion:
Prof. Xichun Hu’s outstanding qualifications, numerous awards, influential professional experience, dedication to teaching, and extensive publication record collectively demonstrate his exceptional impact on the field of oncology. His continuous contributions to cancer research and patient care make him a fitting candidate for the Research for Best Researcher Award.
Publication Tob Noted:
GepLiver: an integrative liver expression atlas spanning developmental stages and liver disease phases
Journal: Scientific Data
Date: June 10, 2023
DOI: 10.1038/s41597-023-02257-1
Contributors: Ziteng Li, Hena Zhang, Qin Li, Wanjing Feng, Xiya Jia, Runye Zhou, Yi Huang, Yan Li, Zhixiang Hu, Xichun Hu, et al.
Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial
Journal: Acta Pharmaceutica Sinica B
Date: May 2023
DOI: 10.1016/j.apsb.2023.02.001
Contributors: Binghe Xu, Qingyuan Zhang, Xichun Hu, Qing Li, Tao Sun, Wei Li, Quchang Ouyang, Jingfen Wang, Zhongsheng Tong, Min Yan, et al.
Clinicopathological, molecular and prognostic characteristics of cancer of unknown primary in China: An analysis of 1420 cases
Journal: Cancer Medicine
Date: January 2023
DOI: 10.1002/cam4.4973
Contributors: Peng Qi, Yifeng Sun, Xin Liu, Sheng Wu, Yixin Wo, Qinghua Xu, Qifeng Wang, Xichun Hu, Xiaoyan Zhou
Phase I Study of A166, a Novel Antibody-Drug Conjugate in Advanced HER2-expressing Solid Tumors
Type: Preprint
Date: November 1, 2022
DOI: 10.21203/rs.3.rs-2179560/v1
Contributors: Xichun Hu, Jian Zhang, Rujiao Liu, Shuiping Gao, Wenhua Li, Yang Chen, Yanchun Meng, Chang Liu, Wenyue Jin, Shuli Yi, et al.
Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)
Journal: Journal of Clinical Oncology
Date: March 1, 2021
DOI: 10.1200/JCO.20.02712
Contributors: Feng-Hua Wang, Xiao-Li Wei, Jifeng Feng, Qi Li, Nong Xu, Xi-Chun Hu, Wangjun Liao, Yi Jiang, Xiao-Yan Lin, Qing-yuan Zhang, et al.